In its largest M&A deal to date, Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals to expand its neuroscience portfolio. Jazz will pay US$220 per American Depositary Share, which values GW at US$7.2 B. The key driver of the deal is Epidiolex® (cannabidiol) oral solution, which is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.